title: [Intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma].
abstract: Four patients with upper urinary tract transitional cell carcinoma were treated with bacillus Calmette-Guerin (BCG) via a percutaneous nephrostomy tube or a retrograde ureteral catheter. A 68-year-old female and an 80-year-old male had carcinoma in situ (CIS) in the left upper urinary tract (cases 1 and 2). A man aged 47 had CIS in the left upper urinary tract, bladder, and prostatic urethra (case 3). CIS in the left upper urinary tract was identified in a woman aged 63 with chronic renal insufficiency (case 4). Two patients (cases 1 and 2) responded to this therapy. In the other two patients nephrectomy was performed due to residual tumor. There were extensive tuberculous granulomas in the kidneys. In one resected kidney (case 4) carcinoma had invaded the renal parenchyma. The reviewed literature showed that BCG perfusion therapy was effective in 71% (27 of 38 renal units) for the upper urinary tract tumors and that there were 5 cases of severe complication, including sepsis in 2, high fever in 2, and ureteral stricture in 1. Based on the fact that the kidney receives a profuse blood supply and that the renal pelvis and ureter have a thin wall, careful management is mandatory to prevent severe adverse effects and insidious tumor progression.
authors.affiliation: Department of Urology, Fukui Medical School, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: B
authors.initials: B
authors.lastname: Miyaji
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Tsuka
authors.forename: O
authors.initials: O
authors.lastname: Wada
authors.forename: Y
authors.initials: Y
authors.lastname: Aoki
authors.forename: H
authors.initials: H
authors.lastname: Akino
authors.forename: K
authors.initials: K
authors.lastname: Muranaka
authors.forename: H
authors.initials: H
authors.lastname: Kanamaru
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: Y
authors.initials: Y
authors.lastname: Imamura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000473:pathology / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014571:Urologic Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine